Source:http://linkedlifedata.com/resource/pubmed/id/19120361
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-1-19
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1365-2141
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
144
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
446-7; author reply 447-8
|
| pubmed:meshHeading |
pubmed-meshheading:19120361-Antineoplastic Agents,
pubmed-meshheading:19120361-Area Under Curve,
pubmed-meshheading:19120361-Humans,
pubmed-meshheading:19120361-Multiple Myeloma,
pubmed-meshheading:19120361-Renal Insufficiency,
pubmed-meshheading:19120361-Risk,
pubmed-meshheading:19120361-Thalidomide,
pubmed-meshheading:19120361-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Lenalidomide in renal insufficiency--balancing the risks and benefits.
|
| pubmed:publicationType |
Letter,
Comment
|